BONRAYBIO (6955) Monthly Revenue

Market: TWSE-listed · Industry: Biotech & Medical · 邦睿生技-創

BONRAYBIO (6955) reported revenue of NT$32.2 million for Oct 2026, +30.1% year on year and +7.3% from the previous month. Revenue for Jan–Oct 2026 was NT$296 million (+19.0% year on year).

Year-on-year revenue growth: 25+ months in a row. →

In Oct 2026, it ranked No. 116 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$17.4 million24/10Nov 2024 NT$21.4 millionDec 2024 NT$24.3 millionJan 2025 NT$21.4 millionFeb 2025 NT$23.8 million25/02Mar 2025 NT$25.9 millionApr 2025 NT$27.4 millionMay 2025 NT$26.7 millionJun 2025 NT$25.7 million25/06Jul 2025 NT$21.7 millionAug 2025 NT$25.3 millionSep 2025 NT$26.2 millionOct 2025 NT$24.7 million25/10Nov 2025 NT$26.1 millionDec 2025 NT$31.4 millionJan 2026 NT$26.4 millionFeb 2026 NT$26.9 million26/02Mar 2026 NT$31.1 millionApr 2026 NT$28.9 millionMay 2026 NT$30 millionJun 2026 NT$33.4 million26/06Jul 2026 NT$26.4 millionAug 2026 NT$30.7 millionSep 2026 NT$30 millionOct 2026 NT$32.2 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$32.2 million+30.1%+7.3%
Sep 2026NT$30 million+14.5%-2.3%
Aug 2026NT$30.7 million+21.4%+16.5%
Jul 2026NT$26.4 million+21.3%-21.0%
Jun 2026NT$33.4 million+30.1%+11.2%
May 2026NT$30 million+12.6%+3.9%
Apr 2026NT$28.9 million+5.3%-7.1%
Mar 2026NT$31.1 million+20.2%+15.6%
Feb 2026NT$26.9 million+13.0%+2.0%
Jan 2026NT$26.4 million+23.5%-16.0%
Dec 2025NT$31.4 million+29.4%+20.3%
Nov 2025NT$26.1 million+22.0%+5.5%
Oct 2025NT$24.7 million+42.4%-5.6%
Sep 2025NT$26.2 million+36.0%+3.6%
Aug 2025NT$25.3 million+18.2%+16.4%
Jul 2025NT$21.7 million+32.8%-15.3%
Jun 2025NT$25.7 million+65.1%-3.8%
May 2025NT$26.7 million+18.6%-2.8%
Apr 2025NT$27.4 million+65.4%+6.1%
Mar 2025NT$25.9 million+46.7%+8.7%
Feb 2025NT$23.8 million+58.2%+11.4%
Jan 2025NT$21.4 million+37.9%-12.0%
Dec 2024NT$24.3 million+13.1%+13.4%
Nov 2024NT$21.4 million+39.4%+23.1%
Oct 2024NT$17.4 million+20.3%-9.8%

Jan–Oct 2026 cumulative: NT$296 million (+19.0% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: BONRAYBIO vs PEC / BONRAYBIO vs Lotus Pharm / BONRAYBIO vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16